Villepinte, November 23, 2018 (8:00 CET) - Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that the OptiVantage® multi-use injector is now CE-marked. This injector is designed for injecting contrast agents used in X-ray (CT scan) medical examinations.
This new solution includes the tried-and-tested OptiVantage® syringe-based injector, a complete range of associated syringes and disposables (manyFill® day set and secufill® patient line), services and support systems (OptiProtect™).
OptiVantage® multi-use will initially be marketed in EMEA from January 2019, then progressively in other regions of the world (Asia and Latin America).
Ad Statistics
Times Displayed: 9690
Times Visited: 30 Brand-New FDA-cleared Advanced Ultrasound Medical Device available for sale or lease to Wound Care Centers or any other Medical Facilities.The Arobella 1000D is designed for non-contact or debridement ultrasound wound healing therapy, or any other wounds
Existing OptiVantage® customers may benefit from an upgrade to easily implement the new multi-use feature.
Guerbet Group Chief Commercial Officer, Diagnostic Imaging, David Hale declared: “We are delighted to be providing radiology professionals with this new multi-use injection solution, which answers market needs without compromising efficiency and patient safety.”
The market targeted by OptiVantage® multi-use represents over half of all CT procedures worldwide.
About OptiVantage®
Launched in 2005, the OptiVantage® injector is a medical device (Class: IIb, CE0123) intended for use by medical imaging and diagnostic health professionals, for injecting radiopaque contrast media and saline into a patient’s vascular system during CT examinations. The new version is adapted to multi-use markets and is available in pedestal and ceiling-mount versions. OptiVantage® is a registered Guerbet trademark.
Refer to the product instructions for use for full information on precautions and the correct use of the medical device.
About Guerbet
Guerbet is a pioneer in the contrast-agent field, with more than 90 years’ experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed across its four centers in France, Israel, and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €807 million in revenue in 2017.
